Members of the ACCC IO Institute Executive Committee discuss why it’s essential to accommodate the unique side-effect profile for immunotherapy patients in survivorship care plans. (features Linda House, RN, BSN, MSM; and Jennie Crews, MD, MMM, FACP)


Featured Resource

Screen Shot 2021-04-06 at 5.04.09 PM 

The dawn and evolution of immunotherapies have given rise to a new class of cancer survivors whose novel experience with these treatments require new tools and resources in survivorship. However, these patients are not typical candidates for receiving traditional survivorship care plans or resources. Current Commission on Cancer standards do not require cancer programs and practices to provide survivorship services to patients treated with immunotherapies. ACCC has created templates to help guide your programs and patients needs.
Explore Survivorship Templates


Related Resources

Survivorship in the Era of IO Lecture Series
Expert panels discuss the unique survivorship needs of IO patients, including improving care coordination and communication within the multidisciplinary team and how to meet patients’ psychosocial and physical well-being needs.

  • Transitioning to Primary Care After IO Treatment
    By Regina Jacob, MD, MSCE, FACP

    While immuno-oncology (IO) therapies have heralded significant advancements in cancer care, there are still many unknowns when it comes to the long-term side effects of these relatively new agents. Since ambulatory care typically involves long-term chronic disease management, these unknowns can often translate to management uncertainty.

  • Survivorship Care in the Era of Immuno-Oncology
    By Sigrun Hallmeyer, MD

    The positive impacts of IO therapy are remarkable, the era of IO has also ushered in new challenges. The efficacy of IO has led to a growing population of patients living with and beyond cancer. This has challenged original concepts of survivorship care, starting with the very definition of “survivorship.”

  • [Publication] IO Wallet Card
    Through its immunotherapy initiative, ACCC has developed a medical wallet card for patients on immunotherapy for cancer. A downloadable print-ready PDF enables cancer programs & practices to have copies printed.
  • [Publication] Survivorship Care Plans for Patients Receiving Immunotherapy
    ACCC’s Immuno-Oncology Institute has developed the Survivorship Care Plans for Patients Receiving Immunotherapy as a resource for cancer programs and practices. and describes processes for developing survivorship care plans (SCPs) for patients treated with immunotherapy, effective practices in SCP design, and considerations for SCP delivery for this patient population.
  • [PODCAST] Ep 04: Survivorship Care After Immunotherapy

    Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.

From Oncology Issues


  • Expanding Access to Bispecific Antibodies in Community Cancer Care
    August 03, 2022
    Learn how ACCC's bispecific antibody initiative “Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management”—developed in partnership with the Society for Immunotherapy of Cancer—will help expand the use of these novel therapies and optimize care for patients with cancer.
  • Micro Inmunoterapia_ACCCBuzz
    ACCC Tools for Immuno-Oncology Survivorship Care
    June 03, 2022
    In recognizing Cancer Immunotherapy Month and National Cancer Survivors Day (June 5), ACCC is highlighting the resources it has created to assist the multidisciplinary team in creating and adapting survivorship care plans to meet these patients’ unique needs and support toxicity management for better outcomes.
    The Best (and Worst) of 2020
    December 30, 2020
  • Sigrun Hallmeyer pic
    June Is Cancer Immunotherapy Month
    June 25, 2020
    In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.